Game Creek Capital LP Has $5.83 Million Stock Position in Medtronic PLC $MDT

Game Creek Capital LP increased its position in shares of Medtronic PLC (NYSE:MDT) by 231.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 61,250 shares of the medical technology company’s stock after buying an additional 42,750 shares during the period. Medtronic accounts for approximately 2.0% of Game Creek Capital LP’s investment portfolio, making the stock its 7th biggest position. Game Creek Capital LP’s holdings in Medtronic were worth $5,833,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MDT. Brighton Jones LLC grew its position in shares of Medtronic by 1,368.0% in the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares during the period. Sivia Capital Partners LLC raised its holdings in shares of Medtronic by 9.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after purchasing an additional 381 shares during the period. AE Wealth Management LLC raised its holdings in shares of Medtronic by 17.1% in the 2nd quarter. AE Wealth Management LLC now owns 10,420 shares of the medical technology company’s stock valued at $908,000 after purchasing an additional 1,521 shares during the period. Wealth Alliance LLC lifted its stake in Medtronic by 5.7% in the 2nd quarter. Wealth Alliance LLC now owns 4,452 shares of the medical technology company’s stock valued at $388,000 after purchasing an additional 242 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in Medtronic by 14.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 632,959 shares of the medical technology company’s stock valued at $55,175,000 after purchasing an additional 79,052 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on MDT shares. JPMorgan Chase & Co. lowered their price target on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. Morgan Stanley raised their price objective on Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. UBS Group reiterated a “neutral” rating and set a $104.00 target price on shares of Medtronic in a research note on Wednesday, February 4th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Finally, Daiwa Securities Group dropped their price target on Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, February 27th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $110.74.

Insider Activity

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.26% of the company’s stock.

Medtronic Trading Down 0.4%

MDT stock opened at $87.05 on Friday. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The company has a market capitalization of $111.77 billion, a PE ratio of 24.25, a price-to-earnings-growth ratio of 2.24 and a beta of 0.71. The company’s 50-day simple moving average is $97.96 and its 200 day simple moving average is $96.84. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The business had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same quarter in the previous year, the company earned $1.38 EPS. The business’s revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s payout ratio is 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).